跳至主要内容
临床试验/EUCTR2005-002654-21-SE
EUCTR2005-002654-21-SE进行中(未招募)不适用

A long-term health economics study of intraduodenal levodopa (Duodopa®) in routine care for patients with advanced idiopathic Parkinson’s disease with severe motor fluctuations and hyper-/dyskinesia. - DAPHNE

Solvay Pharmaceuticals GmbH0 个研究点开始时间: 2005年6月14日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1. Patients on treatment with Duodopa for at least 12 weeks prior to the study.
  • 2. or Duodopa treatment naïve patients. In this case the following must be fulfilled: The investigator considers changing conventional Parkinson´s disease treatment. The criteria in the Summary of Product Characteristics for Duodopa must be fulfilled.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 1. Patients suffering from other diseases that, in the opinion of the investigator, might interfere with the study objectives.
  • 2. Patients that, in the opinion of the investigator, is unable to comply with study requirements.

研究者

相似试验